Instil Bio, Inc. (TIL)
| Market Cap | 152.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.17M |
| Shares Out | 6.53M |
| EPS (ttm) | -11.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,008 |
| Open | 25.91 |
| Previous Close | 26.20 |
| Day's Range | 23.07 - 26.71 |
| 52-Week Range | 6.08 - 92.00 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 100.33 (+329.5%) |
| Earnings Date | Nov 13, 2024 |
About TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $100.33, which is an increase of 329.50% from the latest price.
News
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global ...
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive...
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its ...
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a ...
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its f...
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its...
Instil Bio Announces Strategic Update
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or...
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or...
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing...
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational i...
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 ...
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil confirms cash runway beyond 2026
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
Company anticipates cash resources to provide runway beyond 2026
7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The i...
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
DALLAS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing next-generation tumor infiltratin...
Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - November 21, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in ...
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...